| Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients |
Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, Biospecimen Collection, Endoscopic Biopsy, MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP, Questionnaire Administration |
Recruiting |
| Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis |
Atorvastatin Calcium, Biopsy of Colon, Biospecimen Collection, Placebo Administration, Questionnaire Administration |
Recruiting |
| Testing Obeticholic Acid for Familial Adenomatous Polyposis |
Biopsy, Biospecimen Collection, Gastrointestinal Endoscopy, Obeticholic Acid, Placebo Administration, Questionnaire Administration |
Recruiting |
| Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome |
Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Biopsy, Biospecimen Collection, Colonoscopy, Nogapendekin Alfa, Placebo Administration, Questionnaire Administration |
Recruiting |
| Obeticholic Acid for Prevention in Barrett's Esophagus |
Biospecimen Collection, Esophageal Biopsy, Esophagogastroduodenoscopy, Liver Ultrasonographic Elastography, Obeticholic Acid, Placebo Administration, Questionnaire Administration |
Recruiting |
| CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts |
Ethanol, Normal saline, Paclitaxel + Gemcitabine admixture |
Active, not recruiting |
| ASPirin Intervention for the REDuction of Colorectal Cancer Risk |
Placebo for Aspirin, Aspirin |
Active, not recruiting |
| The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial) |
Placebo, Sulindac 400 MG |
Recruiting |